Table 4 Characteristics of studies included based on treatment regimens: carboplatin plus taxanes
|  | Affiliation | Type of study | Stage of disease | Nº of BRCA1/2 mutated TNBC patients | pCR | Neoadjuvant treatment |
|---|---|---|---|---|---|---|
Gonzalez-Rivera 2016 [39] | Spain | Observational cohort | II-III | 13 | 3 | Cb-D |
Echvarria 2018 [40] | Spain | non- randomized trial | I-III | 9 | 5 | Cb-D |
Sharma 2017 PROGECT [41] | USA and Spain | Clinical trial | I-III | 27 | 16 | Cb-D |
Sharma 2014 [9] | USA | Observational | II-III | 14 | 12 | Cb-D |
Wunderlee 2018 [42] | Germany | Observational cohort | I-III | 15 | 11 | Cb- P |
Wang 2015 [43] | China | Observational cohort | I-III | 10 | 4 | Cb-P |
Menghi 2019 [44] | USA | Phase II Clinical Trial | II-III | 9 | 8 | Cb-P |
Yuan 2020 [45] | USA | Phase II Clinical Trial | II-III | 11 | 8 | Cb-nab-P |